ENDMC
MCID: END057
MIFTS: 77

Endometrial Cancer (ENDMC)

Categories: Cancer diseases, Genetic diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Endometrial Cancer

MalaCards integrated aliases for Endometrial Cancer:

Name: Endometrial Cancer 57 11 73 28 12 53 5 14 75
Endometrial Carcinoma 11 28 53 5 14 16 71
Endometrial Neoplasm 11 28 5 16
Malignant Neoplasm of Endometrium 11 71
Carcinoma, Endometrioid 43 71
Endometrioid Carcinoma 11 16
Endometrial Neoplasms 43 71
Endometrioid Carcinoma of Female Reproductive System 11
Primary Malignant Neoplasm of Endometrium 11
Endometrial Cancer, Susceptibility to 57
Endometrial Carcinoma, Somatic 57
Malignant Endometrial Neoplasm 11
Endometrial Cancer, Familial 57
Carcinoma of the Endometrium 11
Neoplasm of Endometrium 11
Carcinoma Endometrioid 53
Uterine Corpus Cancer 71
Tumor of Endometrium 11
Endometrial Cancers 14
Cancer, Endometrial 38
Endometrial Ca 11
Endmc 73

Characteristics:


Inheritance:

Somatic mutation 57

OMIM®:

57 (Updated 08-Dec-2022)
Miscellaneous:
often seen in cancer predisposition syndromes such as hereditary nonpolyposis colorectal cancer (see )


Classifications:



External Ids:

Disease Ontology 11 DOID:1380 DOID:2871
OMIM® 57 608089
ICD10 31 C54.1
MedGen 40 C0476089
SNOMED-CT via HPO 69 254878006
UMLS 71 C0007103 C0014170 C0206687 more

Summaries for Endometrial Cancer

UniProtKB/Swiss-Prot: 73 A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids.

MalaCards based summary: Endometrial Cancer, also known as endometrial carcinoma, is related to lynch syndrome and mismatch repair cancer syndrome 1. An important gene associated with Endometrial Cancer is MSH6 (MutS Homolog 6), and among its related pathways/superpathways are Disease and Homology Directed Repair. The drugs Fluorodeoxyglucose F18 and Diphenhydramine have been mentioned in the context of this disorder. Affiliated tissues include tissues lining the uterus, tissue lining the uterus and uterus, and related phenotypes are endometrial carcinoma and Decreased viability

Disease Ontology 11 Endometrial cancer: A uterine cancer that is located in tissues lining the uterus.

Endometrial carcinoma: A endometrial cancer that is located in the tissue lining the uterus.

Wikipedia: 75 Endometrial cancer is a cancer that arises from the endometrium (the lining of the uterus or womb). It... more...

More information from OMIM: 608089

Related Diseases for Endometrial Cancer

Diseases related to Endometrial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 949)
# Related Disease Score Top Affiliating Genes
1 lynch syndrome 33.5 PTEN PMS2 MUTYH MSH6 MSH3 MSH2
2 mismatch repair cancer syndrome 1 33.0 PTEN PMS2 MSH6 MSH2 MLH1
3 endometrial adenocarcinoma 32.9 PTEN PMS2 MSH6 MSH2 MLH1 FGFR2
4 cowden syndrome 1 32.9 PTEN PMS2 MUTYH MSH6 MSH2 MLH1
5 lynch syndrome 5 32.7 PMS2 MSH6 MSH2 MLH1
6 endometrial hyperplasia 32.6 PTEN MSH6 MSH2 MLH1
7 adenocarcinoma 32.6 PTEN MSH6 MSH2 MLH1 FGFR2 CDH1
8 lynch syndrome 1 32.6 PMS2 MSH6 MSH3 MSH2 MLH1
9 serous cystadenocarcinoma 32.6 PTEN PMS2 MSH6 MSH2 MLH1 CDH1
10 cervical endometrioid adenocarcinoma 32.5 MSH6 MSH2
11 bap1 tumor predisposition syndrome 32.3 PTEN PMS2 MUTYH MSH6 MSH3 MSH2
12 inherited cancer-predisposing syndrome 32.3 PTEN PMS2 MUTYH MSH6 MSH3 MSH2
13 lynch syndrome 4 32.3 PMS2 MLH1
14 ovarian cancer 32.2 UCA1 PTEN PMS2 NEAT1 MUTYH MSH6
15 mismatch repair cancer syndrome 32.1 PTEN PMS2 MUTYH MSH6 MSH3 MSH2
16 breast cancer 32.0 UCA1 PTEN PMS2 NEAT1 MUTYH MSH6
17 colonic benign neoplasm 31.9 PTEN PMS2 MUTYH MSH6 MSH3 MSH2
18 uterine carcinosarcoma 31.8 PTEN PMS2 MSH6 MSH2 MLH1 FGFR2
19 cowden syndrome 31.8 PTEN PMS2 MUTYH MSH6 MSH3 MSH2
20 colorectal cancer 31.8 UCA1 PTEN PMS2 NEAT1 MUTYH MSH6
21 hereditary breast ovarian cancer syndrome 31.7 PTEN PMS2 MUTYH MSH6 MSH3 MSH2
22 uterine corpus cancer 31.7 PTEN PMS2 MSH6 MSH2 MLH1 MIR200C
23 familial adenomatous polyposis 31.7 PMS2 MUTYH MSH6 MSH3 MSH2 MLH1
24 diffuse gastric cancer 31.6 PTEN PMS2 MUTYH MSH6 MSH2 MLH1
25 female reproductive endometrioid cancer 31.6 PTEN PMS2 MSH6 MSH2 MLH1 BRCA1
26 cervical cancer 31.4 UCA1 PTEN NEAT1 HOTAIR GAS5
27 familial adenomatous polyposis 2 31.4 PTEN PMS2 MUTYH MSH6 MSH3 MSH2
28 signet ring cell adenocarcinoma 31.4 PMS2 MSH6 MSH2 MLH1 CDH1
29 glioblastoma 31.3 PTEN PMS2 MSH6 MSH2 MLH1 HOTAIR
30 endometrioid ovary carcinoma 31.3 PTEN MSH6 MSH2 MLH1
31 mucinous adenocarcinoma 31.2 PMS2 MSH6 MSH2 MLH1
32 adenoma 31.1 PMS2 MUTYH MSH6 MSH2 MLH1 CDH1
33 bladder cancer 31.1 UCA1 PTEN MSH3 MSH2 MLH1 HOTAIR
34 rectal benign neoplasm 31.1 PMS2 MSH6 MSH2 MLH1
35 intestinal benign neoplasm 31.1 PTEN PMS2 MUTYH MSH6 MSH2 MLH1
36 familial colorectal cancer 31.1 MUTYH MSH2 MLH1
37 fallopian tube carcinoma 31.1 PTEN MSH6 MSH2 MLH1 BRCA1
38 pancreatic cancer 31.1 UCA1 PTEN NEAT1 MSH6 MSH2 MLH1
39 melanoma 31.0 UCA1 PTEN MLH1 MIR200C HOTAIR GAS5
40 rectum cancer 31.0 MUTYH MSH6 MSH2 MLH1
41 li-fraumeni syndrome 31.0 PTEN PMS2 MUTYH MSH6 MSH2 MLH1
42 colorectal adenoma 31.0 PMS2 MUTYH MSH6 MSH2 MLH1 CDH1
43 fanconi anemia, complementation group a 31.0 PTEN PMS2 MUTYH MSH6 MSH3 MSH2
44 muir-torre syndrome 31.0 PTEN PMS2 MUTYH MSH6 MSH3 MSH2
45 adrenal cortical carcinoma 31.0 PTEN PMS2 MSH6 MSH2 MLH1 CDH1
46 hepatocellular carcinoma 31.0 UCA1 PTEN PMS2 NEAT1 MSH3 MSH2
47 gastric cancer 30.9 UCA1 PTEN PMS2 NEAT1 MUTYH MSH6
48 colorectal adenocarcinoma 30.9 PTEN PMS2 MSH6 MSH2 MLH1 CDH1
49 duodenum cancer 30.9 PMS2 MUTYH MSH6 MSH2 MLH1
50 skin squamous cell carcinoma 30.9 PTEN PMS2 MSH6 MSH2 MLH1 HOTAIR

Graphical network of the top 20 diseases related to Endometrial Cancer:



Diseases related to Endometrial Cancer

Symptoms & Phenotypes for Endometrial Cancer

Human phenotypes related to Endometrial Cancer:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 endometrial carcinoma 30 HP:0012114

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Neoplasia:
endometrial cancer

Clinical features from OMIM®:

608089 (Updated 08-Dec-2022)

GenomeRNAi Phenotypes related to Endometrial Cancer according to GeneCards Suite gene sharing:

25 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.77 CDH1
2 Decreased viability GR00221-A-2 9.77 BRCA1
3 Decreased viability GR00221-A-3 9.77 BRCA1
4 Decreased viability GR00249-S 9.77 FGFR2
5 Decreased viability GR00301-A 9.77 BRCA1 CDH1 FGFR2 MLH3 MSH2
6 Decreased viability GR00342-S-1 9.77 FGFR2
7 Decreased viability GR00342-S-2 9.77 FGFR2
8 Decreased viability GR00342-S-3 9.77 FGFR2
9 Decreased viability GR00402-S-2 9.77 CDH1
10 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 BRCA1 MLH1
11 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 BRCA1 MLH1
12 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.4 BRCA1 MLH1 MLH3 MSH2 MSH3 MSH6

MGI Mouse Phenotypes related to Endometrial Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.96 BRCA1 CDH1 FGFR2 MLH1 MSH2 MSH3
2 digestive/alimentary MP:0005381 9.81 BRCA1 CDH1 FGFR2 MLH1 MSH2 MSH3
3 cellular MP:0005384 9.73 BRCA1 CDH1 FGFR2 GAS5 MLH1 MSH2
4 integument MP:0010771 9.28 BRCA1 CDH1 FGFR2 MLH1 MSH2 MSH3

Drugs & Therapeutics for Endometrial Cancer

Drugs for Endometrial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 372)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Fluorodeoxyglucose F18 Phase 4
2
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
3
Promethazine Approved, Investigational Phase 3 60-87-7 4927
4
Cetirizine Approved Phase 3 83881-51-0 2678
5
Famotidine Approved Phase 3 76824-35-6 3325 5702160
6
Histamine Approved, Investigational Phase 3 51-45-6 774
7
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
8
Ifosfamide Approved Phase 3 3778-73-2 3690
9
Epirubicin Approved Phase 3 56420-45-2 41867
10
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
11
Medroxyprogesterone acetate Approved, Investigational Phase 2, Phase 3 520-85-4, 71-58-9 6279 10631
12
Levonorgestrel Approved, Investigational Phase 2, Phase 3 797-63-7 13109
13 Orange Approved Phase 2, Phase 3
14
Estradiol Approved, Investigational, Vet_approved Phase 2, Phase 3 50-28-2 5757
15
Ethinylestradiol Approved Phase 2, Phase 3 57-63-6 5991
16
Polyestradiol phosphate Approved Phase 2, Phase 3 28014-46-2
17
Cyproterone acetate Approved, Investigational Phase 2, Phase 3 427-51-0 9880
18
Olaparib Approved Phase 3 763113-22-0 23725625
19
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
20
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
21
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
22
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
23
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3 135329020
24
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
25
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60699 60700
26
Calcium carbonate Approved, Investigational Phase 3 471-34-1
27
Sorbitol Approved, Investigational Phase 3 69-65-8, 50-70-4 453 6251 5780
28
Tamoxifen Approved Phase 3 10540-29-1, 54965-24-1 2733526
29
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
30
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
31
Lenograstim Approved, Investigational Phase 3 135968-09-1
32
Sodium citrate Approved, Investigational Phase 3 68-04-2 23431961
33
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
34
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 3 133585-56-5, 60-18-4, 556-02-5 1153 6057
35
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
36
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
37
Palifosfamide Investigational Phase 3 31645-39-3 100427
38
Cediranib Investigational Phase 3 288383-20-0 9933475
39
Maleic acid Experimental, Investigational Phase 3 110-16-7, 110-17-8 444266 444972
40
Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
41 Carotenoids Phase 3
42 Histamine H1 Antagonists Phase 3
43 Histamine Antagonists Phase 3
44 Anti-Allergic Agents Phase 3
45
Histamine phosphate Phase 3 51-74-1 134614
46 Histamine H1 Antagonists, Non-Sedating Phase 3
47 Vitamin B6 Phase 3
48 Vitamin B 6 Phase 3
49 Aromatase Inhibitors Phase 3
50 Contraceptive Agents, Male Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 1028)
# Name Status NCT ID Phase Drugs
1 Upper Vaginectomy Versus Brachytherapy in Patients With Early Stage Endometrial Cancer Treated With Laparoscopic Surgery: a Randomized Controlled Study. Unknown status NCT00719017 Phase 4
2 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Pilot Study. Unknown status NCT03349463 Phase 4 Fluciclovine F18
3 Does Intraoperative Application of TachoSil Reduce the Number of Lymphocele After Pelvic Lymphadenectomy? Completed NCT03752606 Phase 4
4 Continuation of Treatment and Monitoring of Safety in Patients Treated With LY353381 for Advanced Cancer Completed NCT00190697 Phase 4 arzoxifene
5 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
6 Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer Compared With 18F FDG PET Terminated NCT03423082 Phase 4 18F fluciclovine
7 Role Of Uterine Manipulator in Hysterectomy for Early Stage Endometrial Cancer Unknown status NCT02762214 Phase 3
8 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
9 A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma Unknown status NCT00807768 Phase 3 Carboplatin;Paclitaxel
10 A Multicenter, Prospective, Randomized Trial of the Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma Unknown status NCT01820858 Phase 3 Paclitaxel;Paraplatin (Carboplatin Injection)
11 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Unknown status NCT00719303 Phase 3
12 Assessment of the Impact of Preoperative Stress Reduction on Psychological, Physiological and Immunological Parameters in Women With Gynecological Malignancies - Prospective Randomized Controlled Trial Unknown status NCT00726635 Phase 3
13 Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer Completed NCT02564276 Phase 3
14 Megestrol Acetate Plus LNG-IUS to Megestrol Acetate in Young Women With Early Endometrial Cancer Completed NCT03241914 Phase 2, Phase 3 Megestrol Acetate
15 A Phase III Study of Adjuvant Postoperative Irradiation With or Without Cisplatin/Taxol Chemotherapy Following TAH/BSO for Patients With Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
16 Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients With Stage III &Amp; IV or Recurrent Endometrial Cancer Completed NCT00063999 Phase 3 Carboplatin;Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
17 A Randomised Trial of Lymphadenectomy and of Adjuvant External Beam Radiotherapy in the Treatment of Endometrial Cancer Completed NCT00003749 Phase 3
18 Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer. Completed NCT01767155 Phase 3 AEZS-108 / zoptarelin doxorubicin;doxorubicin
19 Feasibility of a Randomized Controlled Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel Completed NCT04237090 Phase 3 Diphenhydramine;Cetirizine;Lactose pill;Sodium chloride 0.9%
20 Phase III Double-Blind Study Of Depot Octreotide Versus Placebo In The Prevention Of Acute Diarrhea In Patients Receiving Pelvic Radiation Therapy Completed NCT00033605 Phase 3 octreotide acetate
21 A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C) Completed NCT01672892 Phase 3
22 A Randomized Comparison Of Medroxyprogesterone Acetate (MA) And Observation For Prevention Of Endometrial Pathology In Postmenopausal Breast Cancer Patients Treated With Tamoxifen, Phase III Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
23 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
24 A Randomized Trial of Adjuvant Treatment With Radiation Plus Chemotherapy Versus Radiation Alone in High Risk Endometrial Carcinoma Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
25 WHOLE ABDOMINAL RADIOTHERAPY VERSUS CIRCADIAN-TIMED COMBINATION DOXORUBICIN-CISPLATIN CHEMOTHERAPY IN ADVANCED ENDOMETRIAL CARCINOMA -- PHASE III Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
26 Phase III Randomized Study of Adjuvant Pelvic Radiotherapy Versus Observation Alone in Patients With Completely Resected, Stage I or II, High-Grade Uterine Sarcoma Completed NCT00002459 Phase 3
27 A Randomized Phase III Trial for Evaluation of Usefulness of Pelvic Drains After Radical Hysterectomy and Node Dissection (RHND) Completed NCT00003267 Phase 3
28 A Double-Blind Randomized Trial of Pyridoxine Versus Placebo for the Prevention of Doxil-Related Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome) Completed NCT00245050 Phase 3 Placebo;doxorubicin HCL liposome
29 PORTEC-2, Postoperative Radiation Therapy for Endometrial Carcinoma - A Multicenter Randomised Phase III Trial Comparing External Beam Radiation and Vaginal Brachytherapy Completed NCT00376844 Phase 3
30 A Randomized Study of Doxorubicin Plus Cisplatin Versus Doxorubicin Plus Cisplatin Plus 3-Hour Paclitaxel With G-CSF Support in Patients With Primary Stage III & IV or Recurrent Endometrial Carcinoma Completed NCT00003691 Phase 3 cisplatin;doxorubicin hydrochloride;paclitaxel
31 LACE - Laparoscopic Approach to Cancer of the Endometrium: An International Multicenter Randomized Phase 3 Clinical Trial Completed NCT00096408 Phase 3
32 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
33 A Collagen-Fibrin Patch (Tachosil®) for the Prevention of Symptomatic Lymphoceles After Pelvic Lymphadenectomy in Women With Gynecologic Malignancies: a Randomized Clinical Trial Completed NCT01470677 Phase 3 Tachosil fibrin patch
34 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
35 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
36 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Completed NCT00951496 Phase 3 Carboplatin;Cisplatin;Paclitaxel
37 A Phase III Randomized Clinical Trial of Laparoscopic Pelvic and Para-Aortic Node Sampling With Vaginal Hysterectomy and BSO Versus Open Laparotomy With Pelvic and Para-Aortic Node Sampling and Abdominal Hysterectomy and BSO in Endometrial Adenocarcinoma and Uterine Sarcoma, Clinical Stage I, IIA, Grade I, II, III Completed NCT00002706 Phase 3
38 Randomised Phase III Trial of Molecular Profile-based Versus Standard Recommendations for Adjuvant Radiotherapy for Women With Early Stage Endometrial Cancer: PORTEC-4a Trial Recruiting NCT03469674 Phase 3
39 Canadian Multi-arm Multi-stage Randomized Controlled Trial Assessing Front Line Treatment in Serous or p53 Mutant Endometrial Cancer Recruiting NCT04159155 Phase 2, Phase 3 Cisplatin;Carboplatin;Paclitaxel;Niraparib
40 A Phase III Randomised Clinical Trial Comparing Sentinel Node Biopsy With No Retroperitoneal Node Dissection in Apparent Early-Stage Endometrial Cancer Recruiting NCT04073706 Phase 3
41 A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E) Recruiting NCT04269200 Phase 3 olaparib;durvalumab placebo;olaparib placebo;Carboplatin;Paclitaxel
42 A Randomized Phase III Trial of Two Standard Dose Fractionation Regimes for Adjuvant Vaginal Brachytherapy in Early Stage Endometrial Cancer Recruiting NCT03785288 Phase 3
43 Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features: the p53abn-RED Trial, the MMRd-GREEN Trial, the NSMP-ORANGE Trial and the POLEmut-BLUE Trial Recruiting NCT05255653 Phase 2, Phase 3 Olaparib;Chemotherapy;Durvalumab;Medroxyprogesterone Acetate;Megestrol Acetate
44 Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting Recruiting NCT05201547 Phase 3 Carboplatin-Paclitaxel;Dostarlimab
45 Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole vs Ethinylestradiol Cyproterone Plus Metformin in Progestin-insensitive Early-stage Endometrial Cancer and Atypical Hyperplasia Patients With Conservative Treatment Recruiting NCT05316935 Phase 2, Phase 3 GnRHa;Letrozole 2.5mg;Diane-35;MET
46 Clinical Effects of Metformin on Fertility-sparing Treatment for Early Endometrial Cancer Recruiting NCT04792749 Phase 3 Metformin
47 Randomized Phase 3 Study of Selective Versus Sentinel Node Surgical Staging for the Treatment of Endometrial Cancer Recruiting NCT04970368 Phase 3
48 Letrozole as Maintenance Therapy Versus Observation After Adjuvant Treatment on the Prognosis for Post-surgical Endometrial Cancer Patients With Non-specific Molecular Profile: a Superiority Randomized Controlled Trial Recruiting NCT05454358 Phase 2, Phase 3 Letrozole 2.5mg
49 Prehabilitation in Patients With Gynaecological Cancer Planned for Postponed Surgical Management: A Prospective Randomised Trial. Recruiting NCT04789694 Phase 3
50 A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma Recruiting NCT05611931 Phase 3 Selinexor;Matching Placebo for selinexor

Search NIH Clinical Center for Endometrial Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carboplatin
Cyclophosphamide
Leuprolide
Leuprolide Acetate
Medroxyprogesterone
medroxyprogesterone acetate
Megestrol
Megestrol Acetate

Cochrane evidence based reviews: endometrial neoplasms

Genetic Tests for Endometrial Cancer

Genetic tests related to Endometrial Cancer:

# Genetic test Affiliating Genes
1 Endometrial Carcinoma 28 CDH1 MLH3 MSH3 MSH6
2 Endometrial Neoplasm 28
3 Endometrial Cancer 28

Anatomical Context for Endometrial Cancer

Organs/tissues related to Endometrial Cancer:

FMA: Tissues Lining The Uterus, Tissue Lining The Uterus
MalaCards : Uterus, Lymph Node, Breast, Cervix, T Cells, Ovary, Prostate

Publications for Endometrial Cancer

Articles related to Endometrial Cancer:

(show top 50) (show all 28949)
# Title Authors PMID Year
1
Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. 53 62 57 5
17525745 2007
2
Germline mutation prevalence in the base excision repair gene, MYH, in patients with endometrial cancer. 62 57 5
17956577 2007
3
Drug-sensitive FGFR2 mutations in endometrial carcinoma. 53 62 57
18552176 2008
4
MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. 53 62 57
10072435 1999
5
Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair. 53 62 5
8782829 1996
6
The mutational landscape of normal human endometrial epithelium. 62 57
32350471 2020
7
Integrated genomic characterization of endometrial carcinoma. 62 57
23636398 2013
8
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. 62 57
23104009 2012
9
Mitochondrial DNA variant 16189T>C is associated with susceptibility to endometrial cancer. 62 57
12872259 2003
10
Mapping an endometrial cancer tumor suppressor gene at 10q25 and development of a bacterial clone contig for the consensus deletion interval. 62 5
9740666 1998
11
Deletion mapping on chromosome 10q25-q26 in human endometrial cancer. 62 5
8980400 1996
12
Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. 62 5
7728760 1995
13
Exome Sequencing Identifies Biallelic MSH3 Germline Mutations as a Recessive Subtype of Colorectal Adenomatous Polyposis. 5
27476653 2016
14
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 5
25157968 2014
15
First large rearrangement in the MUTYH gene and attenuated familial adenomatous polyposis syndrome. 5
21815886 2011
16
Targeting mutant fibroblast growth factor receptors in cancer. 5
21367659 2011
17
MLH3 and EXO1 alterations in familial colorectal cancer patients not fulfilling Amsterdam criteria. 5
17656264 2007
18
Apert syndrome with preaxial polydactyly showing the typical mutation Ser252Trp in the FGFR2 gene. 5
16440883 2005
19
Beare-Stevenson syndrome: Two South American patients with FGFR2 analysis. 5
12900900 2003
20
The role of hMLH3 in familial colorectal cancer. 5
12702580 2003
21
Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. 5
12588804 2003
22
Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. 5
12606733 2003
23
Abnormal spliceform expression associated with splice acceptor mutations in exon IIIc of FGFR2. 5
12124745 2002
24
Mutation in the FGFR2 gene in a Taiwanese patient with Beare-Stevenson cutis gyrata syndrome. 5
12000365 2002
25
Inherited variants of MYH associated with somatic G:C-->T:A mutations in colorectal tumors. 5
11818965 2002
26
Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. 5
11390973 2001
27
A common mitochondrial DNA variant associated with susceptibility to dilated cardiomyopathy in two different populations. 57
11418155 2001
28
Presence of the Apert canonical S252W FGFR2 mutation in a patient without severe syndactyly. 5
9719378 1998
29
A common mitochondrial DNA variant is associated with insulin resistance in adult life. 57
9498630 1998
30
PTEN1 is frequently mutated in primary endometrial carcinomas. 5
9326929 1997
31
Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis gyrata syndrome. 5
8696350 1996
32
Differential effects of FGFR2 mutations on syndactyly and cleft palate in Apert syndrome. 5
8651276 1996
33
Mutations of the E-cadherin gene in human gynecologic cancers. 5
8075649 1994
34
Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer. 53 62
19960433 2010
35
Differential sensitivity of human endometrial carcinoma cells with different PTEN expression to mitogen-activated protein kinase signaling inhibits and implications for therapy. 53 62
20087603 2010
36
Steroid receptors, HER2/neu and Ki-67, in endometrioid type of endometrial carcinoma: Correlation with conventional histomorphological features of prognosis. 53 62
19446313 2010
37
IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. 53 62
20472848 2010
38
Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells. 53 62
20178884 2010
39
5-Aza-2'-deoxycytidine is a potent inhibitor of DNA methyltransferase 3B and induces apoptosis in human endometrial cancer cell lines with the up-regulation of hMLH1. 53 62
19306077 2010
40
Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancer. 53 62
20153885 2010
41
Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG). 53 62
20304627 2010
42
Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: pathway-based evaluation of candidate genes. 53 62
20053928 2010
43
The universal overexpression of a cancer testis antigen hiwi is associated with cancer angiogenesis. 53 62
20204292 2010
44
FGFR2 mutations are rare across histologic subtypes of ovarian cancer. 53 62
20106510 2010
45
Polymorphism of the ERalpha and CYP1B1 genes in endometrial cancer in a Polish subpopulation. 53 62
20492382 2010
46
Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway. 53 62
20062086 2010
47
High density of peritumoral lymphatic vessels is a potential prognostic marker of endometrial carcinoma: a clinical immunohistochemical method study. 53 62
20374665 2010
48
Expression of Efp, VEGF and bFGF in normal, hyperplastic and malignant endometrial tissue. 53 62
20127022 2010
49
Matrix metalloproteinase-7 (MMP-7) polymorphism is a risk factor for endometrial cancer susceptibility. 53 62
20113256 2010
50
Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients. 53 62
19756737 2010

Variations for Endometrial Cancer

ClinVar genetic disease variations for Endometrial Cancer:

5 (show top 50) (show all 309)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MSH3 NM_002439.5(MSH3):c.1028-1A>T SNV Pathogenic
1040708 rs1008382885 GRCh37: 5:79970801-79970801
GRCh38: 5:80674982-80674982
2 PMS2 NM_000535.7(PMS2):c.2184del (p.Leu729fs) DEL Pathogenic
434030 rs1554294505 GRCh37: 7:6018318-6018318
GRCh38: 7:5978687-5978687
3 PTEN NM_000314.8(PTEN):c.388C>G (p.Arg130Gly) SNV Pathogenic
375958 rs121909224 GRCh37: 10:89692904-89692904
GRCh38: 10:87933147-87933147
4 PTEN NM_000314.8(PTEN):c.1012del (p.Ser338fs) DEL Pathogenic
562182 rs1564568660 GRCh37: 10:89720858-89720858
GRCh38: 10:87961101-87961101
5 MSH6 NM_000179.3(MSH6):c.3922_3940dup (p.Gln1314fs) DUP Pathogenic
433928 rs1553333598 GRCh37: 2:48033710-48033711
GRCh38: 2:47806571-47806572
6 MSH6 NM_000179.3(MSH6):c.755C>G (p.Ser252Ter) SNV Pathogenic
89566 rs267608048 GRCh37: 2:48025877-48025877
GRCh38: 2:47798738-47798738
7 MLH1 NM_000249.4(MLH1):c.588+1G>C SNV Pathogenic
1049107 GRCh37: 3:37053354-37053354
GRCh38: 3:37011863-37011863
8 PMS2 NM_000535.7(PMS2):c.989-1_1144+2del DEL Pathogenic
1049209 GRCh37: 7:6029429-6029587
GRCh38: 7:5989798-5989956
9 MSH6 NM_000179.3(MSH6):c.3647-2_3991del DEL Pathogenic
1049210 GRCh37: 2:48033339-48033778
GRCh38: 2:47806200-47806639
10 PMS2 NM_000535.7(PMS2):c.2446-170_*3del DEL Pathogenic
1049466 GRCh37: 7:6013027-6013343
GRCh38: 7:5973396-5973712
11 MSH6 NM_000179.3(MSH6):c.3980_3981delinsTCAG (p.Asn1327fs) INDEL Pathogenic
1049570 GRCh37: 2:48033769-48033770
GRCh38: 2:47806630-47806631
12 MSH6 NM_000179.3(MSH6):c.3195_3199del (p.Asn1065fs) DEL Pathogenic
988485 rs1384780420 GRCh37: 2:48030580-48030584
GRCh38: 2:47803441-47803445
13 MSH6 NM_000179.3(MSH6):c.976_977insTTGCG (p.Ala326fs) INSERT Pathogenic
1685956 GRCh37: 2:48026097-48026098
GRCh38: 2:47798958-47798959
14 MSH6 NM_000179.3(MSH6):c.3464_3477dup (p.Val1160fs) DUP Pathogenic
1685958 GRCh37: 2:48032072-48032073
GRCh38: 2:47804933-47804934
15 PMS2 NM_000535.7(PMS2):c.2445+1763_*2del DEL Pathogenic
1049762 GRCh37: 7:6013028-6015456
GRCh38: 7:5973397-5975825
16 PMS2 NM_000535.7(PMS2):c.804-267_903+2del DEL Pathogenic
1049913 GRCh37: 7:6035163-6035531
GRCh38: 7:5995532-5995900
17 PMS2 NM_000535.7(PMS2):c.2175-1335_2445+4del DEL Pathogenic
1050329 GRCh37: 7:6017215-6019662
GRCh38: 7:5977584-5980031
18 MSH6 NM_000179.3(MSH6):c.2147_2148del (p.Thr716fs) MICROSAT Pathogenic
428317 rs786204048 GRCh37: 2:48027266-48027267
GRCh38: 2:47800127-47800128
19 PMS2 NM_000535.7(PMS2):c.904-199_988+2del DEL Pathogenic
1050469 GRCh37: 7:6031602-6031887
GRCh38: 7:5991971-5992256
20 AREL1, MLH3 NM_001040108.2(MLH3):c.2221G>T (p.Val741Phe) SNV Pathogenic
5561 rs28756990 GRCh37: 14:75514138-75514138
GRCh38: 14:75047435-75047435
21 MLH3 NM_001040108.2(MLH3):c.885del (p.His296fs) DEL Pathogenic
5563 rs1431264077 GRCh37: 14:75515474-75515474
GRCh38: 14:75048771-75048771
22 PTEN NM_000314.8(PTEN):c.253+1G>A SNV Pathogenic
7820 rs587776667 GRCh37: 10:89690847-89690847
GRCh38: 10:87931090-87931090
23 CDH1 NM_004360.5(CDH1):c.2131C>G (p.Leu711Val) SNV Pathogenic
12231 rs121964871 GRCh37: 16:68857496-68857496
GRCh38: 16:68823593-68823593
24 CDH1 NM_004360.5(CDH1):c.1849G>A (p.Ala617Thr) SNV Pathogenic
12232 rs33935154 GRCh37: 16:68856041-68856041
GRCh38: 16:68822138-68822138
25 MSH2 NM_000251.3(MSH2):c.459del (p.Ala154fs) DEL Pathogenic
1048814 GRCh37: 2:47637324-47637324
GRCh38: 2:47410185-47410185
26 MSH6 NM_000179.3(MSH6):c.2731C>T (p.Arg911Ter) SNV Pathogenic
Pathogenic
89312 rs63751017 GRCh37: 2:48027853-48027853
GRCh38: 2:47800714-47800714
27 MSH3 NM_002439.5(MSH3):c.1148del (p.Lys383fs) DEL Pathogenic
8738 rs587776701 GRCh37: 5:79970915-79970915
GRCh38: 5:80675096-80675096
28 PMS2 NM_000535.7(PMS2):c.538-1G>C SNV Pathogenic
434027 rs988423880 GRCh37: 7:6038907-6038907
GRCh38: 7:5999276-5999276
29 MSH6 NM_000179.3(MSH6):c.10C>T (p.Gln4Ter) SNV Pathogenic
183723 rs786201042 GRCh37: 2:48010382-48010382
GRCh38: 2:47783243-47783243
30 MSH6 NM_000179.3(MSH6):c.3103C>T (p.Arg1035Ter) SNV Pathogenic
Pathogenic
89338 rs63749999 GRCh37: 2:48028225-48028225
GRCh38: 2:47801086-47801086
31 MSH6 NM_000179.3(MSH6):c.3202C>T (p.Arg1068Ter) SNV Pathogenic
Pathogenic
89352 rs63749843 GRCh37: 2:48030588-48030588
GRCh38: 2:47803449-47803449
32 MSH6 NM_000179.3(MSH6):c.3439-2A>G SNV Pathogenic
89391 rs267608098 GRCh37: 2:48032047-48032047
GRCh38: 2:47804908-47804908
33 PMS2 NM_000535.7(PMS2):c.2186_2187del (p.Leu729fs) MICROSAT Pathogenic
91330 rs587779335 GRCh37: 7:6018315-6018316
GRCh38: 7:5978684-5978685
34 PMS2 NM_000535.7(PMS2):c.1261C>T (p.Arg421Ter) SNV Pathogenic
91299 rs587778617 GRCh37: 7:6027135-6027135
GRCh38: 7:5987504-5987504
35 MSH6 NM_000179.3(MSH6):c.2230dup (p.Glu744fs) DUP Pathogenic
183739 rs786201050 GRCh37: 2:48027350-48027351
GRCh38: 2:47800211-47800212
36 MSH2 NM_000251.3(MSH2):c.1566C>G (p.Tyr522Ter) SNV Pathogenic
90699 rs63750224 GRCh37: 2:47693852-47693852
GRCh38: 2:47466713-47466713
37 MSH6 NM_000179.3(MSH6):c.1714C>T (p.Gln572Ter) SNV Pathogenic
421621 rs1064795256 GRCh37: 2:48026836-48026836
GRCh38: 2:47799697-47799697
38 MSH3 NM_002439.5(MSH3):c.2760del (p.Tyr921fs) DEL Pathogenic
253324 rs751326348 GRCh37: 5:80109506-80109506
GRCh38: 5:80813687-80813687
39 MSH3 NM_002439.5(MSH3):c.2686G>T (p.Gly896Ter) SNV Pathogenic
640896 rs777054839 GRCh37: 5:80109433-80109433
GRCh38: 5:80813614-80813614
40 MSH2 NM_000251.3(MSH2):c.1077-1865_1276+742del DEL Pathogenic
1684633 GRCh37: 2:47655013-47657819
GRCh38: 2:47427874-47430680
41 MSH6 NM_000179.3(MSH6):c.1168del (p.Asp390fs) DEL Pathogenic
428404 rs753796271 GRCh37: 2:48026290-48026290
GRCh38: 2:47799151-47799151
42 MSH6 NM_000179.3(MSH6):c.1185_1186del (p.Tyr397fs) MICROSAT Pathogenic
818528 rs1572722039 GRCh37: 2:48026305-48026306
GRCh38: 2:47799166-47799167
43 MSH6 NM_000179.3(MSH6):c.651dup (p.Lys218Ter) DUP Pathogenic
8932 rs63750955 GRCh37: 2:48025772-48025773
GRCh38: 2:47798633-47798634
44 MSH6 NM_000179.3(MSH6):c.3080dup (p.Ser1028fs) DUP Pathogenic
822819 rs1572730021 GRCh37: 2:48028201-48028202
GRCh38: 2:47801062-47801063
45 MSH6 NM_000179.3(MSH6):c.3514dup (p.Arg1172fs) DUP Pathogenic
89404 rs63751327 GRCh37: 2:48032123-48032124
GRCh38: 2:47804984-47804985
46 MSH6 NM_000179.3(MSH6):c.3261del (p.Phe1088fs) DEL Pathogenic
89363 rs267608078 GRCh37: 2:48030640-48030640
GRCh38: 2:47803501-47803501
47 MSH6 NM_000179.3(MSH6):c.3119_3120del (p.Asn1039_Phe1040insTer) DEL Pathogenic
89339 rs267608042 GRCh37: 2:48028240-48028241
GRCh38: 2:47801101-47801102
48 MSH6 NM_000179.3(MSH6):c.1806_1809del (p.Glu604fs) DEL Pathogenic
89224 rs63750735 GRCh37: 2:48026928-48026931
GRCh38: 2:47799789-47799792
49 MSH6 NM_000179.3(MSH6):c.3938_3941dup (p.Gln1314fs) DUP Pathogenic
89485 rs267608126 GRCh37: 2:48033725-48033726
GRCh38: 2:47806586-47806587
50 PTEN NM_000314.8(PTEN):c.209+4_209+7del DEL Pathogenic
92816 rs398123318 GRCh37: 10:89685315-89685318
GRCh38: 10:87925558-87925561

UniProtKB/Swiss-Prot genetic disease variations for Endometrial Cancer:

73
# Symbol AA change Variation ID SNP ID
1 PTEN p.His123Tyr VAR_026260 rs786204931

Cosmic variations for Endometrial Cancer:

8 (show top 50) (show all 12788)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88264503 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.1124G>T p.S375I 23:15822917-15822917 16
2 COSM88264271 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.854C>A p.S285Y 23:15820233-15820233 16
3 COSM88264495 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.514T>A p.C172S 23:15809275-15809275 16
4 COSM87271104 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4316G>A p.R1439Q 16:72798366-72798366 16
5 COSM87278520 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8029G>A p.E2677K 16:72794653-72794653 16
6 COSM102036325 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.762G>T p.E254D 16:72829804-72829804 16
7 COSM87274708 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3925C>T p.R1309* 16:72800069-72800069 16
8 COSM87281210 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4072T>G p.S1358A 16:72798610-72798610 16
9 COSM87291966 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8078G>A p.R2693Q 16:72794604-72794604 16
10 COSM102036916 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3865C>T p.R1289C 16:72796075-72796075 16
11 COSM149332944 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4274T>C p.I1425T 16:72798408-72798408 16
12 COSM87284078 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5754G>T p.K1918N 16:72796928-72796928 16
13 COSM149265473 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8512G>A p.V2838I 16:72794170-72794170 16
14 COSM87289878 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3709C>T p.R1237W 16:72811732-72811732 16
15 COSM102020191 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1387C>A p.L463I 16:72798553-72798553 16
16 COSM149320029 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5623G>A p.E1875K 16:72797059-72797059 16
17 COSM149276742 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1753G>A p.G585S 16:72958393-72958393 16
18 COSM87277220 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5125G>T p.E1709* 16:72797557-72797557 16
19 COSM87275783 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1411G>A p.E471K 16:72958735-72958735 16
20 COSM102020207 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4078C>T p.Q1360* 16:72795862-72795862 16
21 COSM102043844 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6219G>T p.K2073N 16:72793721-72793721 16
22 COSM149319798 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8078G>A p.R2693Q 16:72794604-72794604 16
23 COSM149259590 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1936G>A p.D646N 16:72958210-72958210 16
24 COSM87271751 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9006G>T p.K3002N 16:72793676-72793676 16
25 COSM102042266 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8224C>T p.P2742S 16:72787310-72787310 16
26 COSM149286811 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2875G>A p.D959N 16:72950810-72950810 16
27 COSM149314151 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3709C>T p.R1237W 16:72811732-72811732 16
28 COSM149261368 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4342C>A p.L1448I 16:72798340-72798340 16
29 COSM87283861 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3271G>A p.V1091I 16:72889908-72889908 16
30 COSM87292093 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2459G>A p.R820H 16:72957687-72957687 16
31 COSM102022012 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1832T>C p.L611P 16:72798108-72798108 16
32 COSM149284453 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4653G>T p.K1551N 16:72798029-72798029 16
33 COSM87278783 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8152G>A p.A2718T 16:72794530-72794530 16
34 COSM87292968 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9555A>C p.Q3185H 16:72788721-72788721 16
35 COSM102043873 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.655G>A p.E219K 16:72889782-72889782 16
36 COSM102036330 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.-23-7212G>A p.? 16:72958177-72958177 16
37 COSM149265910 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8849G>A p.R2950H 16:72793833-72793833 16
38 COSM149292038 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8633C>T p.A2878V 16:72794049-72794049 16
39 COSM149293431 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9266A>C p.E3089A 16:72793416-72793416 16
40 COSM149281700 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8617G>A p.E2873K 16:72794065-72794065 16
41 COSM87293150 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3193G>A p.E1065K 16:72950492-72950492 16
42 COSM87289627 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8002C>T p.R2668* 16:72794680-72794680 16
43 COSM87285871 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1969G>A p.G657S 16:72958177-72958177 16
44 COSM102045840 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.-23-9018G>A p.? 16:72959983-72959983 16
45 COSM149322559 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2861C>T p.T954M 16:72950824-72950824 16
46 COSM87293131 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8961G>T p.K2987N 16:72793721-72793721 16
47 COSM149264593 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.629G>A p.G210D 16:72959517-72959517 16
48 COSM102023623 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1183C>T p.R395* 16:72800069-72800069 16
49 COSM149261344 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4129C>A p.L1377I 16:72798553-72798553 16
50 COSM149280950 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2770T>G p.S924A 16:72950915-72950915 16

Copy number variations for Endometrial Cancer from CNVD:

6 (show top 50) (show all 66)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 14799 1 110230418 110236367 Duplication GSTM1 Endometrial cancer
2 16430 1 124300000 247249719 Gain Endometrial cancer
3 16431 1 124300000 247249719 Gain Endometrial cancer
4 16443 1 124300000 247249719 Gain or loss Endometrial cancer
5 30005 1 23900000 28000000 Copy number STMN1 Endometrial cancer
6 38170 10 1 40300000 Gain Endometrial cancer
7 38173 10 1 40300000 Gain or loss Endometrial cancer
8 42809 10 40300000 135374737 Gain Endometrial cancer
9 42810 10 40300000 135374737 Gain or loss Endometrial cancer
10 47133 10 89613174 89718512 Copy number PTEN Endometrial cancer
11 47161 10 89623194 89728531 Loss PTEN Endometrial cancer
12 48495 11 1 52900000 Gain or loss Endometrial cancer
13 55432 11 52900000 134452384 Gain or loss Endometrial cancer
14 61536 12 1 35400000 Gain or loss Endometrial cancer
15 66123 12 25358179 25403863 Amplification KRAS Endometrial cancer
16 75150 13 16000000 114142980 Gain or loss Endometrial cancer
17 82814 14 15600000 106368585 Gain or loss Endometrial cancer
18 89241 15 17000000 100338915 Gain or loss Endometrial cancer
19 97274 16 1 38200000 Gain Endometrial cancer
20 97276 16 1 38200000 Gain or loss Endometrial cancer
21 101463 16 38200000 88827254 Gain or loss Endometrial cancer
22 106793 17 1 22200000 Gain or loss Endometrial cancer
23 108760 17 22200000 78774742 Gain or loss Endometrial cancer
24 119170 18 1 16100000 Gain or loss Endometrial cancer
25 119734 18 16100000 76117153 Gain or loss Endometrial cancer
26 124098 19 1 28500000 Gain or loss Endometrial cancer
27 127175 19 28500000 63811651 Gain or loss Endometrial cancer
28 134355 2 1 93300000 Gain or loss Endometrial cancer
29 146256 2 47483766 47760012 Rearrangement MSH2 Endometrial cancer
30 149784 2 93300000 242951149 Gain or loss Endometrial cancer
31 150416 20 1 27100000 Gain or loss Endometrial cancer
32 151944 20 27100000 62435964 Gain Endometrial cancer
33 151953 20 27100000 62435964 Gain or loss Endometrial cancer
34 157114 21 12300000 46944323 Gain or loss Endometrial cancer
35 160291 22 11800000 49691432 Gain or loss Endometrial cancer
36 163141 22 24376139 24384284 Duplication GSTT1 Endometrial cancer
37 166155 3 1 91700000 Gain or loss Endometrial cancer
38 172027 3 175700000 179000000 Amplification PIK3CA Endometrial cancer
39 175016 3 37009982 37067341 Rearrangement MLH1 Endometrial cancer
40 179466 3 91700000 199501827 Gain or loss Endometrial cancer
41 179984 4 1 50700000 Gain or loss Endometrial cancer
42 187532 4 50700000 191273063 Gain or loss Endometrial cancer
43 200012 5 47700000 180857866 Gain or loss Endometrial cancer
44 203699 6 1 60500000 Gain or loss Endometrial cancer
45 214470 6 60500000 170899992 Gain or loss Endometrial cancer
46 217117 7 1 59100000 Gain or loss Endometrial cancer
47 226563 7 59100000 158821424 Gain or loss Endometrial cancer
48 230833 8 1 45200000 Gain or loss Endometrial cancer
49 240068 8 45200000 146274826 Gain Endometrial cancer
50 240080 8 45200000 146274826 Gain or loss Endometrial cancer

Expression for Endometrial Cancer

Search GEO for disease gene expression data for Endometrial Cancer.

Pathways for Endometrial Cancer

Pathways related to Endometrial Cancer according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.66 BRCA1 CDH1 FGFR2 MLH1 MSH2 MSH3
2
Show member pathways
13.05 PMS2 MUTYH MSH6 MSH3 MSH2 MLH1
3
Show member pathways
12.78 PTEN PMS2 MSH2 MLH1 BRCA1
4
Show member pathways
12.74 MSH6 MSH3 MSH2 MLH1 BRCA1
5
Show member pathways
12.52 PMS2 MUTYH MSH6 MSH3 MSH2 MLH1
6
Show member pathways
12.42 CDH1 FGFR2 MLH1 MSH2 MSH3 MSH6
7 12.35 MUTYH MSH6 MSH2 MLH1 BRCA1
8
Show member pathways
12.06 PMS2 MUTYH MSH6 MSH3 MSH2 MLH1
9 12.05 MSH6 MSH3 MSH2 MLH1 CDH1
10 11.98 PTEN MSH6 MSH2 CDH1 BRCA1
11 11.9 PTEN PMS2 MSH2 MLH1
12 11.73 MIR200C MLH1 MSH2 PTEN
13
Show member pathways
11.65 MSH6 MSH2 BRCA1
14 11.63 MSH2 MLH1 BRCA1
15
Show member pathways
11.57 PMS2 MUTYH MSH6 MSH3 MSH2 MLH1
16 11.25 PTEN MSH6 MSH2 BRCA1
17 10.92 PMS2 MSH6 MSH2 MLH1
18 10.84 UCA1 MIR200C
19
Show member pathways
10.14 PMS2 MLH1

GO Terms for Endometrial Cancer

Cellular components related to Endometrial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 male germ cell nucleus GO:0001673 9.91 MLH3 MLH1 BRCA1
2 MutLalpha complex GO:0032389 9.67 PMS2 MLH1
3 condensed nuclear chromosome GO:0000794 9.58 MLH3 MLH1 BRCA1
4 MutSalpha complex GO:0032301 9.56 MSH6 MSH2
5 condensed chromosome GO:0000793 9.5 MLH3 MLH1 BRCA1
6 MutSbeta complex GO:0032302 9.46 MSH3 MSH2
7 chiasma GO:0005712 9.26 MLH3 MLH1
8 mismatch repair complex GO:0032300 9.17 PMS2 MSH2 MLH3 MLH1

Biological processes related to Endometrial Cancer according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 DNA repair GO:0006281 10.07 PMS2 MUTYH MSH6 MSH3 MSH2 MLH3
2 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.98 MSH6 MSH2 MLH1 BRCA1
3 isotype switching GO:0045190 9.97 MSH6 MSH2 MLH1
4 cellular response to DNA damage stimulus GO:0006974 9.97 BRCA1 MLH1 MLH3 MSH2 MSH3 MSH6
5 negative regulation of DNA recombination GO:0045910 9.93 MSH2 MSH3 MSH6
6 positive regulation of helicase activity GO:0051096 9.88 MSH6 MSH3 MSH2
7 positive regulation of isotype switching to IgG isotypes GO:0048304 9.85 MSH2 MLH1
8 mitotic recombination GO:0006312 9.84 MSH3 MSH2
9 cellular response to indole-3-methanol GO:0071681 9.83 CDH1 BRCA1
10 positive regulation of isotype switching to IgA isotypes GO:0048298 9.81 MSH2 MLH1
11 maintenance of DNA repeat elements GO:0043570 9.77 MSH6 MSH3 MSH2
12 somatic hypermutation of immunoglobulin genes GO:0016446 9.76 MLH1 MSH2 MSH6 PMS2
13 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.65 MSH2 MLH1
14 somatic recombination of immunoglobulin gene segments GO:0016447 9.5 MSH6 MSH3 MSH2 MLH1
15 mismatch repair GO:0006298 9.47 PMS2 MUTYH MSH6 MSH3 MSH2 MLH3

Molecular functions related to Endometrial Cancer according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 10.27 BRCA1 MLH1 MSH2 MSH3 MSH6 PTEN
2 single-stranded DNA binding GO:0003697 10.11 PMS2 MSH3 MSH2 MLH1
3 MutSalpha complex binding GO:0032407 9.88 PMS2 MUTYH MLH1
4 damaged DNA binding GO:0003684 9.84 MSH6 MSH2 BRCA1
5 centromeric DNA binding GO:0019237 9.83 MSH2 MLH3
6 single guanine insertion binding GO:0032142 9.8 MSH6 MSH3 MSH2
7 oxidized purine DNA binding GO:0032357 9.8 MUTYH MSH6 MSH3 MSH2
8 dinucleotide insertion or deletion binding GO:0032139 9.78 MSH3 MSH2
9 MutLalpha complex binding GO:0032405 9.77 MSH2 MSH6 MUTYH
10 dinucleotide repeat insertion binding GO:0032181 9.76 MSH3 MSH2
11 single thymine insertion binding GO:0032143 9.73 MSH6 MSH2
12 ATP-dependent DNA damage sensor activity GO:0140664 9.73 PMS2 MSH6 MSH3 MSH2 MLH3 MLH1
13 guanine/thymine mispair binding GO:0032137 9.7 MLH1 MSH2 MSH3 MSH6
14 mismatched DNA binding GO:0030983 9.32 PMS2 MSH6 MSH3 MSH2 MLH3 MLH1

Sources for Endometrial Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....